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The relationship between risk of death from clinical stage 1 cutaneous
melanoma and thickness of primary tumour: no evidence for steps in risk
M. Keefe & R.M. Mackie
For and on behalfofthe Scottish Melanoma Group, the Department ofDermatology, University ofGlasgow and the Department of
Dermatology, Royal South Hants Hospitat, Southampton, UK.
Summary Previous reports have suggested that the relationship between survival and thickness of primary
cutaneous malignant melanoma is not linear, but that there are natural breakpoints at which survival worsens
in a step fashion. Nine hundred and ninety-seven cases of primary cutenaous malignant melanoma less than
9.75 mm thick, excised in Scotland between 1979 and 1983 inclusive, were examined to see if this could be
confirmed. An adjusted Cox's regression analysis showed that age, sex, site and thickness were all significant
predictors of survival. Thickness was grouped either empirically or by the breakpoints reported by other
authors. It was then entered into a model either as a regressor or as a factored variable. The ranges
0-9.75 mm and 0-2 mm were studied separately. In the 0-9.75 mm range the factored variable was a
statistically significant better fit than the regressor for each set of breakpoints, including an empirical analysis
with eight groups. This suggests that there is no single best fit and that a step-effect is unlikely. Across the
0-2 mm range there was no significant improvement in the fit if thickness was entered as a factored variable,
again indicating that a step effect is unlikely. We argue that there is no biological or statistical evidence to
support the existence of natural breakpoints.
It has consistently been shown in multivariate analyses from
different countries that the thickness of the primary tumour,
measured from the granular cell layer of the epidermis to the
deepest malignant cell, is the most important independent
predictor of survival from clinical Stage cutaneous malig-
nant melanoma (Balch et al., 1978; Sondergaard et al., 1985;
Bonett et al., 1986; Meyskens et al., 1988).
It is helpful to the clinician to be able to categorise
patients into groups with different probabilities of survival
and several authors have done this using thickness as the
grouping variable. Breslow (1970) originally reported on 98
cases of Stage 1 melanoma. All patients in whom the primary
tumour was less then 0.76 mm thick and was at Clark level II
or III survived more than 5 years. All tumours that were at
Clark level IV or V were already thicker than this and
survival was worse. Breslow formed empirical thickness
groups for prognostic purposes but Balch et al. (1978) tried
to be more scientific. They studied 339 patients and grouped
them into three categories. The final groups were the result of
repeated comparisons of actuarial survival curves for differ-
ent sets of groups which were repeated until the 'P' value
from a generalised Wilcoxon test was maximised. The break-
points were at 0.76mm and 4mm.
Two other authors, however, have gone a step further and
argued that there is a biological reason to categorise patients
in this way. Day et al. (1981a) studied 598 patients and
reported that mortality increased with increasing thickness in
a series of quantum leaps analogous to a rising staircase.
They used a logistic regression method to argue that there
were 'natural breakpoints' in thickness at 0.85 mm, 1.70 mm
and 3.60 mm. They argued that investigators should use these
breakpoints to form logical groups into which patients
should be stratified for trials. They also suggested that
studies of patients on the margins of these groups would help
to answer questions about melanoma growth and metastases.
Most recently Meyskens et al. (1988) used yet another
method to study 377 patients with very similar breakpoints
identified.
We have studied data from the Scottish Melanoma Group
database to see whether there is a smooth or stepwise rela-
tionship between thickness and survival. This is by far the
largest published study to address this question. The analysis
is not intended to be an exhaustive study of all possible
prognostic variables for melanoma survival, but we have
examined a number of variables which other authors have
found to be important and included them in the model.
Materials and methods
The Scottish Melanoma Group (SMG) receives reports of
virtually all cases of malignant melanoma in Scotland and is
routinely validated against cancer registries. There are separ-
ate SMG registers covering the West of Scotland, Lothian,
Grampian, Highland and Tayside and data from all five
centres has been collected for analysis. Most cases have been
followed-up annually to ascertain dates for recurrence or
death. The analysis is restricted to patients registered between
1979 and 1983 inclusive on whom a minimum of 5-year
follow-up is available.
The sample comprised 1,100 cases of clinical Stage
primary cutaneous malignant melanomas of Clark level II or
more. Nine cases had missing data for the variables studied
and were excluded. Fifty-five cases were lost to follow-up.
For consistency with other reports the analysis was restricted
to 997 cases less than 9.75 mm thick. Thickness was catego-
rised into eight levels with melanomas less than 0.76 mm as a
baseline group and six groupings at 1 mm increments to
6.75 mm. From 6.75 mm to 9.75 mm the numbers were
rather small and were combined. This choice of categories
gave regular increments across the range within which break-
points have been reported. It also avoided having whole
numbers at the margins of the intervals, which may be
important as our data showed marked digit preference in
reporting of thickness.
However, because these intervals are relatively large in
relation to the intervals between breakpoints which pre-
viously have been described we cannot exclude, from this
single analysis, the presence of breakpoints in the 0-2 mm
range. Therefore, in a further analysis, cases up to 2 mm
thick were studied more closely. Cases were grouped at
0.1 mm thickness intervals from 0.7 mm to 2 mm. The
0.7 mm baseline was necessary because of the small number
of deaths at thinner levels. Deaths from causes other than
melanoma were regarded as censored at the date of death.
Cox's proportional hazards regression model was used for
survival analysis. The hazard ratio was plotted against
tumour thickness. To test whether a step function or a
smooth relationship between thickness and survival was most
likely the following test was done for each thickness range
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separately. The deviance was calculated with thickness cate-
gorised and entered into the model as a factored variable.
The mean thickness for each factor level was then calculated
and substituted for the ordinal factor level. This term was
then entered as a regressor and the deviance calculated for
this model. The test is to subtract the deviance derived from
the first model from the deviance derived from the second.
The residual deviance gives a x2 test on the difference in the
degrees of freedom. In a separate model thickness was also
used in the original units and entered as a regressor with
several orders of polynomial. Estimates of 5-year survival
rate for sub-groups were made with the Kaplan-Meier techni-
que. Confidence intervals are presented where appropriate.
Results
Cases with Breslow thickness up to 9.75 mm thick
The first results presented are for 997 melanomas up to
9.75 mm thick. The mean thickness was 2.50 mm (s.d. 2.02,
range 0.03-9.60 mm). The male:female ratio was 296:701.
The mean age was 56 years (s.d. 17.3, range 5-96 years).
There were 233 deaths from melanoma and 101 deaths from
other causes.
The following variables were tested: age, sex, site, histo-
genetic type (lentigo maligna melanoma, superficial spreading
melanoma, nodular melanoma, acral lentiginous melanoma,
unclassified melanoma), histological level of invasion (Clark
level) and thickness. All variables were statistically significant
predictors of survival in unadjusted analyses, but when
adjusted for other variables only age, sex, thickness and site
were significant (Table I). Level of invasion (P = 0.305) and
histogenetic type (P = 0.795) were not significant. Male sex,
lesions on the trunk, volar or subungual sites, increasing age
and increasing thickness were associated with worse survival.
A recent report has suggested that melanomas on an 'axial'
site (head, neck, trunk, volar and subungual) have poorer
survival than those on an extremity (all other sites) and that
this is an independent predictor of survival (Clark et al.,
1989). This grouping was not significant. in a separate adjust-
ed analysis (P = 0.667). Our coding scheme did not permit
grouping into BANS and non-BANS sites (Day et al., 1981b).
If thickness is categorised as above and entered into the
model as a factored variable and the hazard ratios for each
thickness interval plotted at the mid-point of each interval,
the hazard ratios increase as an approximately linear func-
tion of thickness with one outlying observation (deviance =
2813.263, likelihood ratio statistic = 217.031 on 13 d.f.,
P<0.001). We suspect that the outlying observation for the
4.76-5.75 mm group is an aberrant result as subsequent
points continue in a linear fashion (Figure 1). If thickness is
categorised, but used as a regressor, the fit is less good
(deviance = 2846.124, likelihood ratio statistic = 184.170 on
7 d.f., P<0.001) and the difference is statistically significant
(residual deviance = 32.861 on 6 d.f., P<0.001). If the
breakpoints of other authors are used, in all cases the model
with thickness entered as a factor is a statistically signifiacnt
better fit than when it is entered as a regressor, but no one
set of breakpoints is an outstanding fit (Table II).
Table I Cases less than 9.75 mm thick
S-year surv. Univariate HR Multivariate HR1
n % 95% CI expo(p) 95% CI expo(p) 95% CI
Age (continuous) 997 - - 1.02 1.01-1.03 1.01 1.00-1.02
Site Group 1
Head and neck 214 82 75-87
Trunk 192 73 65-79 1.69 1.12-2.58 1.89 1.22-2.93
Upper limb 128 75 66-82 1.40 0.86-2.28 1.59 0.97-2.63
Lower limb 380 81 76-85 1.14 0.77-1.69 1.55 1.01-2.35
Volar or subungual 83 51 38-63 3.08 1.93-4.90 2.06 1.29-3.29
Site Group 2
Head, neck, trunk 489 73 68-77
volar or subungual.
Extremities 508 80 76-83 0.76 0.59-0.99
Sex
Male 296 66 60-72
Female 701 81 77-84 0.57 0.44-0.74 0.60 0.46-0.80
Histogenic type
Lent. mal. melanoma 147 84 76-90
Super. spreading 523 83 79-86 1.30 0.80-2.10
Nodular 221 65 58-71 2.94 1.80-4.80
Unclassified 42 54 37-69 3.78 2.00-7.15
Acral lentiginous 64 60 45-73 2.94 1.61-5.39
Clark's level
II 138 97 89-99
III 245 84 79-89 6.38 2.29-17.77
IV 519 72 67-76 12.27 4.54-33.16
V 95 51 40-62 22.51 8.06-62.83
Thickness (mm)
<0.76 219 95 90-98
0.76-1.75 227 89 84-93 3.16 1.49-6.70 3.07 1.45-6.53
1.76-2.75 182 79 72-85 6.23 3.03-12.81 5.73 2.77-11.32
2.76-3.75 131 65 56-73 10.83 5.30-22.14 9.61 4.68-19.76
3.76-4.75 100 58 46-69 13.40 6.46-27.81 11.95 5.73-24.90
4.76-5.75 53 41 27-55 26.00 12.27-55.09 22.19 10.37-47.47
5.76-6.75 35 51 31-68 17.83 7.79-40.81 15.86 6.90-36.47
6.76-9.75 50 42 27-56 25.60 12.04-54.42 22.00 10.25-47.20
Continuous variable 997 - - 1.40 1.33-1.47 2.34 1.88-2.93
Thickness squared 997 - - - - 0.94 0.92-0.97
Survival from clinical Stage I primary cutaneous malignant melanoma first registered in Scotland
between 1979 and 1983 inclusive. Cases 0-9.75 mm thick, n = 997. HR = hazard ratio. 'All results
adjusted for other variables in model. Only statistically significant results are shown. Hazard ratios for
sex, age and site derived from analysis using thickness factored on eight levels. Hazards ratios for
thickness as a continuous variable were derived from a separate analysis.600 M. KEEFE & R.M. MACKIE
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Figure 1 Hazard ratio by tumour thickness for primary cutan-
eous melanoma in Scotland registered between 1979 and 1983.
Hazard ratios are plotted at the mid-point of each thickness
category. Range 0-9.75 mm thick. n = 997.
.
. .
.
.
* * U
* .
. .
.
.
0 0.2 0.4 0.6 0.8 1 1.2 1.4
Tumour thickness (mm)
1.6 1.8 2
Figure 2 Hazard ratio by tumour thickness for primary cutan-
eous melanoma in Scotland registered between 1979 and 1983.
Hazard ratios are plotted at the mid-point of each thickness
category. Range 0-2 mm thick. n = 520.
Table II Cases less than 9.75 mm thick
5-year surv. Univariate HR Multivariate HR"
n % 95% CI expo(p) 95% CI expo(p) 95% CI
Balch breakpoints
<0.76 219 95 90-98
0.76-3.99 558 80 76-83 5.90 3.00-11.62 5.42 2.74-10.70
>4.00 220 47 39-55 20.09 10.14-39.81 16.76 8.41-33.39
Day breakpoints
<0.85 245 95 90-97
0.85-1.69 186 88 82-92 2.50 1.27-4.94 2.44 1.23-4.82
1.70-3.60 316 74 69-79 5.96 3.32-10.69 5.33 2.96-9.60
>3.60 250 50 43-57 14.13 7.94-25.14 12.18 6.81-21.79
Meyskens breakpoints
<0.85 245 95 90-97
0.85-1.94 242 88 82-91 2.62 1.37-5.01 2.50 1.31-4.79
1.95-3.99 290 72 66-77 6.68 3.73-11.98 6.02 3.34-10.85
4.00 220 47 39-55 15.74 8.81-28.12 13.42 7.47-24.11
5-yearsurvival ratesandhazardratiosforthicknesscategoriesderivedfromBalch(1978), Day(198la)
andMeyskens(1988). Cases0-9.75 mmthick, n = 997. Unitsofdevianceremovedbyfittingcategorised
thickness as a factored variable rather than as a continuous variable:
Using Balch's breakpoints:
factor - deviance = 2840.800, LRS = 189.495 on 8 d.f., P<0.001
regressor - deviance = 2853.999, LRS = 176.296 on 7 d.f., P<0.001
residual deviance = 13.199 on I d.f., P<0.001
Using Day's breakpoints:
factor - deviance = 2834.229, LRS = 196.066 on 9 d.f., P<0.001
regressor - deviance = 2845.280, LRS = 185.014 on 7 d.f., P<0.001
residual deviance = 11.051 on 2d.f., P<0.01
Using Meysken's breakpoints:
factor - deviance = 2823.613, LRS = 206.681 on 9 d.f., P<0.001
regressor - deviance = 2834.955, LRS = 195.340 on 7 d.f., P<0.001
residual deviance = 11.342 on 2 d.f., P<0.01
HR = hazard ratio. aAll results adjusted for other variables in model (age, sex and site).
When thickness was fitted as a regressor in the original
units (mm to two decimal places) with several orders of
polynomial, there were significant linear and quadratic
effects, with the hazard ratio rising in an approximately
linear fashion to about 6.75 mm thick then falling with in-
creasing thickness. However, the shape of the curve is prob-
ably excessively influenced by outliers in the higher thickness
categories.
Cases with Breslow thickness up to 2 mm
This interval was studied more closely to ensure that no
breakpoints were missed in this range. The fit was not im-
proved by entering thickness as a factored variable rather
than as a regressor. This was true whether 0.1 mm increments
were used or whether breakpoints described previously by
other authors or the potentially best-fitting breakpoints (from
examination of Figure 2) were entered. The distribution of
the hazard ratios with thickness at 0.1 mm intervals is shown
in Figure 2. Sex was not a significant variable in the adjusted
analysis in this thickness range. It was not possible to
examine for breakpoints below 0.7 mm because of the small
number of deaths amongst thinner lesions.
Discussion
For melanomas less than 9.75 mm thick there appears to be a
continuous, probably linear, relationship between survival
and thickness adjusted for sex, age and site. We hoped to
unequivocally exclude the presence of breakpoints but we
have not been able to do so. In all analyses over the
0-9.75 mm range thickness fits better as a factored variable
than as a regressor but no one set of breakpoints has an
advantage suggesting that there is no best fit. Indeed, our
empirical use of eight groups also fitted better as a factored
variable than as a regressor and it is unlikely that there
would be as many as seven breakpoints. This suggests that a
step effect is unlikely.
We made a separate study of all cases less than 2 mm thick
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v
1tA_ r-SURVIVAL AND THICKNESS OF CUTANEOUS MELANOMA 601
Table III Cases less than 2 mm thick
5-year surv. Unadjusted HR Adjusted HRa
n % 95% CI expo(1) 95% CI expo(p) 95% CI
Age (continuous) 520 - - 1.02 1.00-1.04 1.02 1.00-1.05
Site Group 1
Head and neck
Trunk
Upper limb
Lower limb
Volar or subungual
Site Group 2
Head, neck, trunk
volar or subungual.
Extremities
Sex
Male
Female
Histogenic type
Lent. mal. melanoma
Super. spreading
Nodular
Unclassified
Acral lentiginous
Clark's level
II
III
IV
V
Thickness (mm)
<0.70
0.71-0.80
0.81-0.90
0.91-1.00
1.01 -1.10
1.11-1.20
1.21-1.30
1.31 -1.40
1.41-1.50
1.51-1.60
1.61-1.70
1.71-1.80
1.81-1.90
1.91-2.00
Continuous variable
117
105
63
209
26
248
272
91
88
95
92
79
88
92
82-95
79-93
85-98
86-95
56-91
83-92
88-95
133 86 79-92
387 92 88-94
98
342
44
13
23
135
187
194
4
205
36
28
37
19
25
22
17
19
17
18
29
12
36
520
91
92
84
64
89
96
92
85
96
90
89
85
88
92
91
88
95
75
89
86
92
76
82-96
88-95
69-92
28-86
61-97
89-99
86-95
78-89
91-98
71-97
69-96
61-95
61 -97
71-98
68-89
61-97
68-99
46-90
62-97
66-94
54-99
57-87
1.76 0.76-3.99
0.58 0.16-2.15
1.10 0.50-2.43
3.51 1.24-9.90
2.41 0.98-5.94
0.65 0.17-2.46
1.05 0.45-2.48
2.71 0.93-7.90
0.63 0.36-1.09
0.68 0.38-1.22
1.24 0.54-2.81
2.40 0.87-6.63
4.93 1.44- 16.86
1.22 0.25-5.87
2.94 0.98-8.80
6.36 2.25-17.99
3.95
3.70
3.69
3.55
2.16
2.67
6.63
1.81
9.04
5.46
4.40
2.73
9.05
2.80
1.25-12.44
0.96-14.34
1.08-12.62
0.74-17.12
0.45-10.41
0.55-12.83
1.94-22.66
0.22-14.70
2.64-30.93
1.41-21.13
1.29-15.03
0.34-22.20
3.44-23.81
1.72-4.56
4.62
3.63
3.95
3.60
2.30
2.31
8.13
1.42
9.18
5.99
3.99
1.95
8.09
2.52
1.43-14.91
0.93- 14.08
1.14-13.65
0.74-17.48
0.47-11.17
0.48-11.19
2.31-28.64
0.17-11.62
2.58-32.61
1.53-23.47
1.16-13.79
0.24-16.15
3.05-21.45
1.55-4.09
Survival from clinical Stage 1 primary cutaneous malignant melanoma first registered in Scotland
between 1979and 1983inclusive. Cases0-2 mmthick, n = 520. HR = hazard ratio. 'All resultsadjusted
forothervariablesinmodel.Onlystatisticallysignificantresultsareshown. Hazardratiosforageandsite
derived from analysis using thickness factored in eight levels. Hazards ratios for thickness as a
continuous variable were dervied from a separate analysis.
using fine 0.1 mm increments to ensure that there were no
breakpoints in that range which might have been overlooked.
It was not possible to use a baseline group less than 0.7 mm
thick as although there were seven deaths under 0.5 mm there
were no deaths in the 0.5-0.7 mm range so these cases
logically have to be grouped with the thinner lesions. We
cannot, therefore, exclude the presence of a breakpoint in the
0.5-0.7 mm range. All the analyses done in this range show-
ed that thickness fitted as well as a regressor as it did as a
factored variable. The results, therefore, indicate that there
are no breakpoints in the 0.7-2 mm range.
The analyses of other authors (Balch et al., 1978; Day et
al., 1981a; Meyskens et al., 1988) have all had drawbacks.
The sample sizes have been relatively small and the distribu-
tion of thickness in all series is grossly skewed towards thin
tumours. Categorisation by thickness into small subgroups
was likely to lead to very small numbers in some groups,
particualrly in thicker categories. In the analyses used it was
inevitable that breakpoints would be found due to the nature
of the techniques, but these may, however, be statistical
artefacts.
In conclusion, clinicians will doubtless continue to find it
useful to group patients for prognostic purposes but there is
no biological reason to believe that there are natural break-
points and our results do not support the view that they
exist. We think that the risk of death is probably a linear
function of tumour thickness and the onus should be on the
proponents of natural breakpoints to provide better bio-
logical and statistical evidence for their existence.
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Table IV Cases less than 2 mm thick
5-year surv. Univariate HR Multivariate HR'
n % 95% CI expo(p) 95% CI expo(p) 95% CI
'Best-fit' breakpoints
<0.81 241 95 91-97
0.81-1.40 148 89 81-93 2.48 1.81-5.19 2.42 1.15-5.10
1.41-2.00 131 84 76-89 4.04 2.01-8.12 3.50 1.72-7.11
Day breakpoints
<0.85 245 95 90-97
0.85-1.69 186 88 82-92 2.55 1.29-5.03 2.50 1.26-4.97
1.70-2.00 89 83 73-90 3.72 1.79-7.73 3.16 1.50-6.62
Meyskens breakpoints
<0.85 245 95 90-97
0.85-1.94 242 88 82-91 2.65 1.39-5.07 2.50 1.30-4.81
1.95-2.00 33 79 60-90 4.85 2.01-11.72 4.25 1.75-10.32
5-year survival rates and hazard ratios for thickness categories dervied from Day (1981a) and
Meyskens (1988) together with the visually best fit from Figure 2. Cases 0-2 mm thick, n = 520.
Units of deviance removed by fitting categorised thickness as a factored variable rather than as a
continuous variable:
Using 'best fit' breakpoints:
factor - deviance = 581.032, LRS = 29.028 on 7 d.f., P<0.001
regressor - deviance = 581.862, LRS = 28.198 on 6 d.f., P<0.001
residual deviance = 0.830 on I d.f., P>0.25.
Using Day's breakpoints:
factor - deviance = 583.013, LRS = 27.046 on 7 d.f., P<0.001
regressor - deviance = 584.260, LRS = 25.800 on 6 d.f., P<0.001
residual deviance = 1.247 on I d.f., P>0.25.
Using Meysken's breakpoints:
factor - deviance = 581.910, LRS = 28.150 on 7 d.f., P<0.001
regressor - deviance = 582.026, LRS = 28.033 on 6 d.f., P<0.001
residual deviance = 0.116 on I d.f., P>0.5.
HR = hazard ratio. 'All results adjusted for age and site.
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